CHMP restricts use of Pletal(Otsuka)and Ekistol(Lacer) to treat Intermittant Claudication
The European Medicines Agency�s Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol-containing medicines in the treatment of Intermittent Claudication � a condition where poor blood supply to the leg muscles causes pain and affects the ability to walk � should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.
The recommendations follow a review of current evidence which indicates that the modest benefits of these medicines, i.e. their ability to increase the distance patients are able to walk, are only greater than their risks, in particular the risks of side effects affecting the heart or serious bleeding, in a limited subgroup of patients. Cilostazol-containing medicines are available in the EU under the names Pletal(Otsuka) and Ekistol (Lacer).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins